Our Products News
-
Ribo Submits Phase 2b Clinical Trial Application for world’s first siRNA FXI inhibitor in atrial fibrillationRibo Submits Phase 2b Clinical Trial Application for world’s first siRNA FXI inhibitor in atrial fibrillationApril 14, 2026 -
Ribo expands beyond the liver with RiboPepSTAR™ – enabling targeted siRNA delivery to multiple organsRibo expands beyond the liver with RiboPepSTAR™ – enabling targeted siRNA delivery to multiple organsMarch 20, 2026 -
Ribo to present ex-hepatic delivery data at RNA Leaders Europe ConferenceRibo has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences.March 17, 2026 -
Ribo's PCSK9-targeting siRNA drug RBD7022 is about to launch Phase III clinical trials in China.Ribo's PCSK9-targeting siRNA drug RBD7022 is about to launch Phase III clinical trials in China.March 2, 2026 -
Recent advances in factor XI (FXI) inhibition are reshaping the landscape of anticoagulation therapyRecent advances in factor XI (FXI) inhibition are reshaping the landscape of anticoagulation therapyFebruary 9, 2026 -
Ribo Receives Phase II Clinical Approval for ApoC3-targeting siRNA drug RBD5044 in ChinaRibo Receives Phase II Clinical Approval for ApoC3-targeting siRNA drug RBD5044 in ChinaJanuary 23, 2026